vitro and in vivo studies for novel therapeutic approaches. Roberto - - PowerPoint PPT Presentation

vitro and in vivo studies for novel
SMART_READER_LITE
LIVE PREVIEW

vitro and in vivo studies for novel therapeutic approaches. Roberto - - PowerPoint PPT Presentation

Fifth annual Ri.MED Symposium Priming the therapeutic pipeline: new strategies for drug discovery Palermo, October 24 th 2011 Neuronal oxidative injury in the development of the epileptic disease: in vitro and in vivo studies for novel


slide-1
SLIDE 1

Neuronal oxidative injury in the development of the epileptic disease: in vitro and in vivo studies for novel therapeutic approaches.

Roberto Di Maio Ph.D.

Ri.MED Foundation, Italy Pittsburgh Institute for Neurodegeneratine Diseases

  • Dept. of Neurology

University of Pittsburgh

Fifth annual Ri.MED Symposium

Priming the therapeutic pipeline: new strategies for drug discovery

Palermo, October 24th 2011

slide-2
SLIDE 2

reduced Oxidized

Resting cell Stimulation of proliferation Mild oxidative insult release of reactive metals Severe oxidative insult mitochondrial DNA and DNA oxidative damage

Initiation of apoptosis

Apoptosis Extreme

  • xidation

Oxidation of Caspases Apoptosis Necrosis Adaptative response Transcription factors Protective systems

O

X

Redox state

Redox state and biological events

slide-3
SLIDE 3

Introduction

Epileptic disorders

  • The most frequent neurodegenerative diseases after stroke
  • Affect approximately 50 million of the world population
  • 500,000 Italian have been diagnosed with epilepsy
  • Contribute 0.5% of the global burden of disease
  • Approximately 30% of epileptic patients are unresponsive to AEDs
  • Temporal Lobe Epilepsies (TLEs) are the most common forms of

pharmaco-resistant epilepsy

Prevention of epilepsy is one of the main Epilepsy Research Benchmarks

slide-4
SLIDE 4

Pilocarpine model of epilepsy Human Temporal Lobe Epilepsy NMDAR-mediated

  • xidative damage and

exctitoxicity Apoptosis and Cell death Loss of neurons NMDAR subunits altered stoichiometry

The human Temporal Lobe Epilepsy Pilocarpine as model of Temporal Lobe Epilepsy

Glutamatergic paroxysm

?

Hippocampal damage

slide-5
SLIDE 5
  • Investigate the oxidative-related biochemical mechanisms

involved in altered NMDARs stoichiometry

  • Develop a simple experimental model of hyper excitability

aimed to dissect the cellular mechanisms of epileptogenesis

Experimental design

Primary hippocampal neurons PILO 4µM

* * *

Horowitz, Milanese, Di Maio et al., Antiox. Redox Signal, 2011

Ratio SS/SH

slide-6
SLIDE 6

Pilocarpine alters NMDA receptor expression and function in hippocampal neurons: NADPH oxidase and ERK1/2 mechanisms

Roberto Di Maio, Pier G. Mastroberardino, Xiaoping Hu, Laura Montero and J. Timothy Greenamyre Neurobiology of Disease, 2011

* * * *

Summary 1 PILO in primary hippocampal neurons recapitulates some features

  • f epilepsy- associated hyper excitability

Primary hippocampal neurons PILO 4µM Time point: 24 hours PILO model of TLE in rat PILO 360 mg/Kg Time point: 24 hours

slide-7
SLIDE 7
  • How can thiol oxidation contribute to the development
  • f chronic epilepsy?
  • How can NR2B subunit lead to the development of the

epileptic disease?

Oxidative stress and NR2B containing NMDA autoreceptor up-regulation: relevance in epilepsy

slide-8
SLIDE 8

Oxidative stress and NR2B containing NMDA autoreceptor up-regulation: relevance in epilepsy

N-Acetylcysteine (NAC) 300µM

Primary hippocampal neurons PILO 4µM Time point: 48 hours PILO model of TLE in rat PILO 360 mg/Kg; Ifenprodil 30 mg/Kg Time point: 48 hours

slide-9
SLIDE 9

Summary 2

Apoptosis Cell death

pERK NMDAR2A upregulation

Oxidative stress and NR2B subunit’s function/expression could constitute selective targets for novel therapeutic approaches aimed to prevent the development of chronic epileptic diseases.

slide-10
SLIDE 10

How can cannabinoids prevent chronic epilepsy?

The pharmacological stimulation of CB1 receptor during the epileptic

  • nset could be effective to prevent the consequences of glutamatergic

paroxysm and the occurrence of the epileptic chronic brain damage

  • CB1 receptor stimulation exerts antiepileptic effects in

animal models of acute epilepsy

  • Cannabinoids are neuroprotective against oxidative

stress and neuronal inflamation

slide-11
SLIDE 11

Experimental Design

Adult male Sprague-Daweley rats (initial weight: 250-280g) PILO 360 mg/Kg i.p. WIN 55,212-2 (CB1 receptor agonist; 2mg/kg s.c.)

Behavioral studies

slide-12
SLIDE 12

Results

Behavioral studies

RACINE SCALE

(MODIFIED BY PINEL AND ROVNER)

0 = immobility 1 = facial automatisms 2 = head myoclonus 3 = forelimb myoclonus 4 = rearing 5 = falling 6 = more than three falls 7 = wild running 8 = tonic–clonic seizures

slide-13
SLIDE 13

Results

Hippocampal sclerosis

Timm’s Staining

slide-14
SLIDE 14

Results

Oxidative stress

slide-15
SLIDE 15

Results

NR2A NR2B subunits expression

slide-16
SLIDE 16

Results

GABA and CB1 receptor expression

slide-17
SLIDE 17

Conclusions

CB1 receptor could represent a potential target for novel therapeutic approaches aimed to prevent the development of chronic TLE, the most common intractable form of epilepsy.

slide-18
SLIDE 18

Future Directions

  • Provide further insight into the efficacy of CB1 receptor agonists

in preventing the oxidative stress-mediated epileptogenesis in adult and in developmental brain

  • Investigate the role of oxidative stress in the aberrant neuronal

proliferation of the epileptic hippocampus

  • Test the potential efficacy of CB1 receptor agonists in the

prevention of the epileptic abnormal neurogenesis

slide-19
SLIDE 19

Acknowledgements

  • J. Timothy Greenamyre, MD, PhD

Professor & Vice-Chair of Neurology Director, Pittsburgh Institute for Neurodegenerative Diseases University of Pittsburgh

Xiaoping Hu

Cell cultures

Laura Maria Montero

Immunohistochemistry

Jason R. Cannon, PhD

University of Pittsburgh Neurochemistry